Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1756 to 1770 of 8905 results

  1. Pridopidine for treating Huntington's disease [ID6525]

    Awaiting development Reference number: GID-TA11637 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398]

    Awaiting development Reference number: GID-TA11500 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Radium-223 dichloride with enzalutamide for treating asymptomatic or mildly symptomatic hormone-relapsed metastatic prostate cancer with bone metastases [ID6512]

    In development Reference number: GID-TA11657 Expected publication date:  07 April 2027

    Technology appraisal guidance
    In development

  4. Sevabertinib for untreated HER2-positive advanced non-small-cell lung cancer [ID6616]

    Awaiting development Reference number: GID-TA11814 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]

    In development Reference number: GID-TA10990 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Dersimelagon for treating erythropoietic protoporphyria and X-linked protoporphyria in people 12 years and over [ID6160]

    In development Reference number: GID-TA11085 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor [ID6476]

    In development Reference number: GID-TA11584 Expected publication date:  08 December 2027

    Technology appraisal guidance
    In development

  8. Triheptanoin for treating long-chain fatty acid oxidation disorders [ID3891]

    In development Reference number: GID-TA11473 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Trastuzumab deruxtecan with or without pertuzumab for untreated HER2-positive metastatic breast cancer [ID6548]

    Awaiting development Reference number: GID-TA11723 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Tovorafenib for treating relapsed or refractory paediatric low-grade glioma with BRAF fusion or rearrangement or BRAF V600 mutation in people 6 months and over ID6557

    In development Reference number: GID-TA11693 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. LAM-561 with radiotherapy and temozolomide for treating IDH1 wild-type glioblastoma [ID4022]

    Awaiting development Reference number: GID-TA11741 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Sacituzumab govitecan for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6592]

    Awaiting development Reference number: GID-TA11769 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Elranatamab for treating relapsed or refractory multiple myeloma after treatments including anti-CD38 antibody and lenalidomide therapy [ID6591]

    Awaiting development Reference number: GID-TA11753 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Iptacopan for treating primary IgA nephropathy [ID6640]

    Awaiting development Reference number: GID-TA11844 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Zanubrutinib with rituximab for untreated mantle cell lymphoma when a stem cell transplant is unsuitable [ID6641]

    Awaiting development Reference number: GID-TA11843 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development